NASDAQ: TSHA
Taysha Gene Therapies Inc Stock Ownership - Who owns Taysha Gene Therapies?

Insider buying vs selling

Have Taysha Gene Therapies Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Sukumar NagendranPresident and Head of RD2026-07-10200,000$6.24
$1.25MSell
Sukumar NagendranPresident and Head of RD2026-04-10200,000$4.46
$892.00kSell
Sukumar NagendranPresident and Head of RD2026-04-1019,021$1.71
$32.53kBuy
Kamran AlamCHIEF FINANCIAL OFFICER2026-02-041,655$4.52
$7.48kSell
Sean P. NolanChief Executive Officer2026-01-2641,312$4.61
$190.45kSell
Kamran AlamCHIEF FINANCIAL OFFICER2026-01-2623,849$4.61
$109.94kSell
Sukumar NagendranPresident and Head of RD2026-01-2626,918$4.61
$124.09kSell
Sean P. NolanChief Executive Officer2026-01-23136,789$4.75
$649.75kSell
Sukumar NagendranPresident and Head of RD2026-01-2389,132$4.75
$423.38kSell
Kamran AlamCHIEF FINANCIAL OFFICER2026-01-2378,968$4.75
$375.10kSell

1 of 3

TSHA insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when TSHA insiders and whales buy or sell their stock.

TSHA Shareholders

What type of owners hold Taysha Gene Therapies Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ra Session Ii2.77%9,012,837$55.79MInsider
Audentes Therapeutics Inc2.23%7,266,342$44.98MInsider
Paul B. Manning1.64%5,333,333$33.01MInsider
Sean P. Nolan1.36%4,443,802$27.51MInsider
John A. Stalfort Iii0.63%2,060,849$12.76MInsider
Kamran Alam0.44%1,442,131$8.93MInsider
Sukumar Nagendran0.29%936,410$5.80MInsider
Suyash Prasad0.16%530,589$3.28MInsider
Phillip B. Donenberg0.07%241,289$1.49MInsider
Laura Sepplorenzino0.04%127,178$787.23kInsider

1 of 3

TSHA vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
TSHA0.09%9.67%Net SellingNet Selling
AUPH0.06%14.09%Net BuyingNet Buying
GHRS0.08%21.86%
SEPN0.10%58.91%Net SellingNet Selling
NBTX0.01%0.00%

Taysha Gene Therapies Stock Ownership FAQ

Who owns Taysha Gene Therapies?

Taysha Gene Therapies (NASDAQ: TSHA) is owned by 0.09% institutional shareholders, 9.67% Taysha Gene Therapies insiders, and 90.23% retail investors. Ra Session Ii is the largest individual Taysha Gene Therapies shareholder, owning 9.01M shares representing 2.77% of the company. Ra Session Ii's Taysha Gene Therapies shares are currently valued at $55.79M.

If you're new to stock investing, here's how to buy Taysha Gene Therapies stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.